Waters

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis

Jessalynn P. Wheaton, Erin E. Chambers, and Kenneth J. Fountain

APPLICATION BENEFITS

- Simple, one-step sample preparation method
- Universal protocol requiring no method development
- Removal of >95% of residual phospholipids relative to LLE with MTBE
- Eliminates extract transfer and evaporation steps compared to traditional LLE
- Reduces sample variability and eliminates sources of suppression

WATERS SOLUTIONS

■ Ostro[™] sample preparation products

KEY WORDS

Ostro, phospholipids, matrix effects, liquid-liquid extraction

INTRODUCTION

Bioanalytical methods are under constant pressure from regulatory agencies to meet requirements for matrix effects, accuracy and precision, more challenging lower limits of quantitation (LLOQ) and incurred sample reanalysis (ISR). Sample preparation has become an increasingly important aspect of meeting these challenges. The introduction of more sensitive mass spectrometers has further increased the burden on sample preparation and on the generation of the cleanest extracts possible. Liquid-liquid extraction (LLE) is a common sample preparation choice in regulated bioanalysis. LLE can generate high analyte recoveries, clean extracts, and is perceived as low cost. Depending on the compounds analyzed, however, LLE methods must often be optimized. Extraction solvents may need to be acidified, basified or low percentages of more polar solvents may be required to simultaneously achieve high recoveries for metabolites and related compounds, as well as the primary analyte. In many cases, the choice of LLE solvent may lead to extracts particularly saturated with phospholipids (PLs). As well as contributing to matrix effects, residual PLs can build-up on the analytical column and the LC system. PL build-up may cause analyte signal variability, suppression of MS response, and potentially lead to instrument down-time. Similar to LLE, phospholipid removal (PLR) plates also provide high analyte recoveries and clean extracts. In addition to these benefits, the Ostro 96-well sample preparation plate provides a simple, one-step method which achieves high recoveries for diverse analyte types without optimization. In addition, the need to transfer, evaporate, and reconstitute the extract is eliminated, thus, significantly decreasing the sample preparation time. To demonstrate the effectiveness of this technique and its broad applicability in bioanalytical assays, the Ostro sample preparation plate and a generic LLE method were compared for the extraction of a diverse group of pharmaceutical drugs. With no method development, analyte recovery was high, >75%, for polar and nonpolar, acidic, and basic analytes alike, and 95% of PLs were removed relative to LLE. Ostro extraction of 96 samples was achieved in half the time relative to 96-well LLE and in less than 1/10th the time if LLE was performed in individual tubes.

[APPLICATION NOTE]

EXPERIMENTAL ACQUITY UPLC Conditions

Column:	ACQUITY UPLC® BEH C ₁₈ ,			
	2.1 x 50 mm, 1.7 μm			
Mobile Phase A:	0.1% NH_4OH in H_2O			
Mobile Phase B:	Acetonitrile			
Flow Rate:	0.6 mL/min			
Gradient:	Time Profile (min) %A %B		Curve	
	0.0	95	5	6
	2.0	2	98	6
	3.0	2	98	6
	3.1	95	5	6
	3.5	95	5	6
Injection Volume:	30.0 μL			
Injection Mode:	Partial Loop			
Column Temperature:	35 ℃			
Sample Temperature:	15 °C			
Strong Needle Wash:	60:40 ACN:IPA + 0.2% conc. HCOOH (600 μL)			
Weak Needle Wash:	80/20 H ₂ 0/MeOH (200 μL)			

Waters Xevo[™] TQ-S Conditions, ESI⁺

Capillary Voltage:	3.0 kV			
Desolvation Temp:	550 °C			
Cone Gas Flow:	150 L/Hr			
Desolvation Gas Flow:	1000 L/Hr			
Collision Cell Pressure:	2.6 x 10 ⁽⁻³⁾ mbar			
MRM transition monitored FSL+ See Table 1				

2



Figure 1. Representative structure and molecular weights of the selected drug compounds used in this study.

Analyte	Precursor Mass	Daughter Mass	Cone Voltage (V)	Collision Energy (eV)
Oxycodone	316.3	256.1	30	28
Valethamate	306.2	163.0	34	24
Niflumic Acid	283.3	265.1	34	20
Ketoprofen	255.3	209.2	28	14
Progesterone	315.1	96.6	34	20
Hydrocortisone	363.1	327.1	36	14

Table 1. MRM transitions, collision energies, and cone voltages for a diverse group of drug compounds.

SAMPLE PREPARATION PROTOCOL

Extraction using the Ostro plate was performed using 200 µL of pre-spiked or blank rabbit plasma which was extracted with 600 μL of 1% HCOOH in acetonitrile (Figure 2). LLE was performed using 200 µL of pre-spiked or blank rabbit plasma and extracted with 1 mL of 100% MTBE in a centrifuge tube. The tube was vortexed for 1 minute, centrifuged at 3500 rpm for 5 minutes, and supernatant transferred to a 2 mL 96-well plate. To facilitate direct comparison, all extracts were post-spiked and dried under nitrogen gas in order to determine recovery. The samples were reconstituted in a constant volume of 200 μL 50/50 MeOH/H₂O prior to injection onto the LC/MS/MS system so that the Ostro plate and LLE sample results could be compared to one another. Eluates from the Ostro plate were usually direct injected.



Figure 2. Ostro plate basic plate protocol.

RESULTS AND DISCUSSION

Recovery was calculated for both the Ostro plate and LLE and the averages (n=8) were compared for the group of drug compounds (Figure 3). The average recovery for the Ostro plate across all analytes was 83%. The average for LLE across all analytes was 47%. The levels of PLs remaining after each sample preparation technique were also compared. This was accomplished by quantifying five common PLs from the Ostro and LLE extracts. Area counts were summed, and the resultant data indicated that >95% of PLs were removed relative to LLE (Figure 4). To visually demonstrate the remaining levels of residual phospholipids, the MRM transition 184>184 is shown for both traditional LLE and extraction in-well using the Ostro plate (Figure 5). For the cleanest samples, Ostro sample preparation plates can be combined with LLE. LLE was performed as previously discussed and the supernatant passed through Ostro plates. The resulting eluate was then dried down and reconstituted following the original method. This combined sample prep method resulted in the removal of >99.9% of residual PLs (Figure 6) relative to LLE alone. To demonstrate the effect these residual PLs can have on signal variability, the peak area for a representative compound was monitored during overnight analytical runs of Ostro and LLE extracts. The resulting %RSD values were 5% for Ostro samples and 25% for LLE samples. This signal variability observed in LLE samples may be detrimental when performing incurred sample reanalysis (ISR) to fully validate the drug method. In bioanalysis, high throughput is also important. A time table was created to compare sample preparation time for 96 samples extracted using an Ostro plate, LLE in a 96-well plate, and traditional LLE in centrifuge tubes (Figure 7). The total time required to prepare 96 plasma samples was 11 minutes using the Ostro plate, 21 minutes for LLE in 96-well format, and 164 minutes for LLE samples in individual centrifuge tubes.



Figure 3. Average analyte recoveries for a mix of drug compounds comparing the Ostro sample preparation plate to LLE with 100% MTBE.

3

[APPLICATION NOTE]



Figure 4. Comparison of the sum of phospholipid levels between samples extracted in-well using the Ostro 96-well plate and samples extracted using the traditional LLE method in tubes n=8 for each technique. The 5 phospholipids summed have precursor masses of 496, 524, 704, 758, and 806.



Figure 5. MRM transition 184>184 was monitored to visually demonstrate total remaining residual PLs from the Ostro plate and LLE using 100% MTBE.



Figure 6. Comparison of the sum of phospholipid levels between samples extracted in-well using the Ostro 96-well plate and samples extracted using the traditional LLE method in tubes n=8 for each technique. The 5 phospholipids summed have precursor masses of 496, 524, 704, 758, and 806..



Figure 7. A comparison of the time required to prepare 96 plasma-based samples using an Ostro 96-well plate, LLE in 96-well format, and LLE in centrifuge tubes. Four LLE tubes were vortexed simultaneously. Pipetting for the 96-well plates was performed using a multi-channel pipette.

CONCLUSIONS

- Ostro 96-well sample preparation plates,
 - are a simple, one-step sample prep alternative to LLE in bioanalysis.
 - utilize a generic method that requires no method development for analytes with diverse chemical properties.
 - allow for direct injection of eluates, which eliminates the evaporation step required for LLE extracts.
 - remove >95% of residual phospholipids when compared to traditional LLE.
 - provide for a significant reduction in sample prep time relative to LLE in 96-well format or LLE in individual tubes.
- A combination of the Ostro plate and LLE removes >99.9% of residual phospholipids.

5

Sales Offices

Austria and European Export	Norway 47 6 384 6050			
(Central South Eastern Europe, CIS and Middle East) //3 1 877 18 07	Poland 48 22 833 4400			
Australia 61 2 9933 1777	Puerto Rico 1 787 747 8445			
Belgium 32 2 726 1000	Russia/CIS 7 495 727 4490/ 290 9737			
Brazil 55 11 4134 3788	Singapore 65 6593 7100			
Canada 1 800 252 4752	Spain 34 93 600 9300			
China 86 10 5293 6688	Sweden 46 8 555 115 00			
Czech Republic 420 2 617 11384	Switzerland 41 56 676 7000			
Denmark 45 46 59 8080	Taiwan 886 2 2501 9928			
Finland 358 9 5659 6288	United Kinadom 44 208 23			
France 33 1 30 48 72 00	6100			
Germany 49 6196 400 600	All other countries:			
Hong Kong 852 2964 1800	Waters Corporation U.S.A.			
Hungary 36 1 350 5086	1 800 252 4752			
India 91 80 2837 1900	www.waters.com			
Ireland 353 1 448 1500				
Italy 39 02 265 0983				
Japan 81 3 3471 7191				
Korea 82 2 6300 4800				
Mexico 52 55 52 00 1860				

The Netherlands 31 76 508 7200

Waters Corporation

UKAS QUALITY MANAGEMENT 001

©2011 Waters Corporation. Produced in the U.S.A. July 2011 720004051EN KK-PDF

34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com



© 2011 Waters Corporation. Waters, The Science of What's Possible, ACQUITY UPLC, Xevo, and Ostro are trademarks of Waters Corporation.